A protocol for a randomised double-blind placebo-controlled feasibility study to determine whether the daily consumption of flavonoid-rich pure cocoa has the potential to reduce fatigue in people with relapsing and remitting multiple sclerosis (RRMS)
Tóm tắt
Dietary interventions including consumption of flavonoids, plant compounds found in certain foods, may have the ability to improve fatigue. However, to date, no well-designed intervention studies assessing the role of flavonoid consumption for fatigue management in people with MS (pwMS) have been performed. The hypothesis is that the consumption of a flavonoid-rich pure cocoa beverage will reduce fatigue in pwMS. The aim of this study is to determine the feasibility and potential outcome of running a trial to evaluate this hypothesis. Using a randomised (1:1) double-blind placebo-controlled feasibility study, 40 men and women (20 in each trial arm) with a recent diagnosis (< 10 years) of relapsing and remitting MS (RRMS) and who are over 18 years of age will be recruited from neurology clinics and throughout the Thames Valley community. During a 6-week nutrition intervention period, participants will consume the cocoa beverage, high flavonoid or low flavonoid content, at breakfast daily. At baseline, demographic factors and disease-related factors will be assessed. Fatigue, activity and quality of life, in addition to other measures, will be taken at three visits (baseline, week 3 and week 6) in a university setting by a researcher blinded to group membership. Feasibility and fidelity will be assessed through recruitment and retention, adherence and a quantitative process evaluation at the end of the trial. We will describe demographic factors (age, gender, level of education) as well as disease-related factors (disease burden scores, length of time diagnosed with MS) and cognitive assessment, depression and quality of life and general physical activity in order to characterise participants and determine possible mediators to identify the processes by which the intervention may bring about change. Feasibility (recruitment, safety, feasibility of implementation of the intervention and evaluation, protocol adherence and data completion) and potential for benefit (estimates of effect size and variability) will be determined to inform future planned studies. Results will be presented using point estimates, 95% confidence intervals and p values. Primary statistical analysis will be on an intention-to-treat basis and will use the complete case data set. We propose that a flavonoid-enriched cocoa beverage for the management of fatigue will be well received by participants. Further, if it is implemented early in the disease course of people diagnosed with RRMS, it will improve mobility and functioning by modifying fatigue. Registered with ISRCTN Registry. Trial registration No:
ISRCTN69897291
; Date April 2016
Tài liệu tham khảo
Strober L. Fatigue in multiple sclerosis: a look at the role of poor sleep. Front Neurol. 2015;6. https://doi.org/10.3389/fneur.2015.00021.
Campagnolo N, Johnston S, Collatz A, Staines D, Marshall-Gradisnik S. Dietary and nutrition interventions for the therapeutic treatment of chronic fatigue syndrome/myalgic encephalomyelitis: a systematic review. J Hum Nutr Diet. 2017;30:247–59.
Wolkorte R, Heersema D, Zijdewind I. Muscle fatigability during a sustained index finger abduction and depression scores are associated with perceived fatigue in patients with relapsing-remitting multiple sclerosis. Neurorehab Neur Rep. 2015;29:796-802.
Gilgun-Sheki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neuro. 2004;251:261–8.
Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3T. Brain. 2005;128:1016–25.
Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation and treatment. Sleep. 2010;33:1061–7.
Besler HT, Çomoglu S. Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr Neuro. 2003;6:189–96.
Grosso C, Valentao P, Ferreres F, Andrade P. The use of flavonoids in central nervous system disorders. Curr Med Chem. 2013;20:4694–719.
Sathyapalan T, Campion P, Beckett S, Rigby AS, Atkin SL. High cocoa polyphenol rich chocolate improves the symptoms of chronic fatigue. Endocrine Abs. 2006;12:68.
Coe S, Axelsson E, Murphy V, Santos M, Collett J, Clegg M, Izadi H, Harrison JM, Buckingham E, Dawes H. Flavonoid rich dark cocoa may improve fatigue in people with multiple sclerosis, yet has no effect on glycaemic response: an exploratory trial. Clin Nutr ESPN. 2017;21:20-5.
Rieckmann P, Albrecht M, Kitze B, Weber T. Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol. 1995;37:82–8
Katsavos S, Anagnostouli M. Biomarkers in multiple sclerosis: an up-to-date overview. Mult Scl Int. 2013. https://doi.org/10.1155/2013/340508
Ortiz GG, Pacheco-Moisés FP, Bitzer-Quintero OK, et al. Immunology and oxidative stress in multiple sclerosis: clinical and basic approach. Clin Dev Imm. 2013. https://doi.org/10.1155/2013/708659
Rönnbäck L, Hansson E. On the potential role of glutamate transport in mental fatigue. J Neuroinflammation. 2004;1. https://doi.org/10.1186/1742-2094-1-22.
Sathyapalan T, Beckett S, Rigby AS, Mellor DD, Atki SL. High cocoa polyphenol rich chocolate may reduce the burden of the symptoms in chronic fatigue syndrome. Nutr J. 2010;9. https://doi.org/10.1186/1475-2891-9-55.
Wu J, Gao W, Wei J, Yang J, Pu L, Guo C. Quercetin alters energy metabolism in swimming mice. App Phy Nutr Metab. 2012;37:912–22.
Herlofson K, Ongre SO, Enger LK, Tysnes OB, Larsen JP. Fatigue in early Parkinson’s disease. Minor inconvenience or major distress? Eur J Neurol. 2012;19:963–8.
Clarke CL, Taylor J, Crighton LJ, Goodbrand JA, McMurdo MET, Witham MD. Validation of the AX3 triaxial accelerometer in older functionally impaired people. Ag Clini Exper Res. 2017;29:451–7.
Washburn RA, McAuley E, Katula J, Mihalko SL, Boileau RA. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;46:153–62.
Bingham SA, Gill C, Welch A, Day K, Cassidy A, Khaw KT, Sneyd MJ, Key TJA, Roe L, Day NE. Comparison of dietary assessment methods in nutritional epidemiology: weighed records v. 24h recalls, food frequency. questionnaires and estimated diet records. B J Nut. 1994;72:619–42.
Cella D, Lai JS, Nowinski CJ, et al. Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neuro. 2012;78:1860–7.
Goldman MD, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler. 2008;14:383–90.
Viaar A, Wade DT. The Adult Memory and Information Processing Battery (AMIPB) test of information-processing speed: a study of its reliability and feasibility in patients with multiple sclerosis. Clin Rehab. 2003;17:386–93.
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Qual Life Res. 2011;20:1727–36.
Kuspinar A, Finch L, Pickard S, Mayo NE. Using existing data to identify candidate items for a health state classification system in multiple sclerosis. Qual Life Res. 2013. https://doi.org/10.1007/s11136-013-0604-5.
Wade D, Collin C. The Barthel ADL Index: a standard measure of physical disability? Int Dis Stud. 1988;10:64–7.
Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361–70.
Thirunarayan MA, Kerrigan DC, Rabuffetti M, Della Croce U, Saini M. Comparison of 3 methods for estimating vertical displacement of center of mass during level walking in patients. Gait Posture. 1996;4:306–14.
Kerrigan DC, Viramontes BE, Corcoran PJ, LaRaia PJ. Measured versus predicted vertical displacement of the sacrum during gait as a tool to measure biomechanical gait performance. Am J Phys Med Rehabil. 1995;74:3–8.
Sim J. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. J Clin Epid. 2012;65:301–8.
Browne R. On the use of a pilot sample for sample size determination. Stat Med. 1995;14:1933–40
Borm G, Fransen J, Lemmens W. A simple sample size formula for analysis of covariance in randomized clinical trials. J Clin Epidemiol. 2007;60:1234–8.
Altman DG. Measurement in medicine: the analysis of method comparison studies. The Statistician. 1983;32:307–17